We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

7 hedge funds and large institutions have $1.1M invested in Seelos Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

17% more funds holding

Funds holding: 6 → 7 (+1)

37% less capital invested

Capital invested by funds: $1.75M → $1.1M (-$649K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
7
Holders Change
+1
Holders Change %
+16.67%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$69.5K
2
Citadel Advisors
Citadel Advisors
Florida
+$34.7K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$34.7K
2
HVC
Healthcare Value Capital
New Jersey
-$31K
3
MML Investors Services
MML Investors Services
Massachusetts
-$13K
4
FANJ
Financial Architects (New Jersey)
New Jersey
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$883K – – –
Geode Capital Management
2
Geode Capital Management
Massachusetts
$43K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$36K +$69.5K +2 New
Vanguard Group
4
Vanguard Group
Pennsylvania
$33K -$34.7K -1 -50%
AAP
5
Ardsley Advisory Partners
Connecticut
$29K – – –
Citadel Advisors
6
Citadel Advisors
Florida
$24K +$34.7K +1 New
BlackRock
7
BlackRock
New York
$16K – – –
Susquehanna International Group
8
Susquehanna International Group
Pennsylvania
$7K – – –
UBS Group
9
UBS Group
Switzerland
$7K – – –
California Public Employees Retirement System
10
California Public Employees Retirement System
California
$5K – – –
FWM
11
Frontier Wealth Management
Missouri
$4K – – –
VF
12
Virtu Financial
New York
$4K – – –
Northern Trust
13
Northern Trust
Illinois
$3K – – –
CG
14
Colony Group
Massachusetts
$2K – – –
WP
15
WealthShield Partners
North Carolina
$2K – – –
FDCDDQ
16
Federation des caisses Desjardins du Quebec
Quebec, Canada
$134 – – –
HVC
17
Healthcare Value Capital
New Jersey
– -$31K -1 Closed
FANJ
18
Financial Architects (New Jersey)
New Jersey
– -$1K – –
MML Investors Services
19
MML Investors Services
Massachusetts
– -$13K – –

SEEL Hedge Fund Activity: Q4 2018 in Review

7 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q4 2018, worth a combined $1.1M — down 37% from $1.75M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new SEEL positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $69.5K. The largest seller was Vanguard Group, cutting an estimated $34.7K.

  • 7 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q4 2018, up from 6 in Q3 2018.
  • Funds reported $1.1M of Seelos Therapeutics, Inc. Common Stock stock for Q4 2018, down 37% quarter-over-quarter.
  • 2 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q4 2018 and 1 closed out, a net change of +1 holder.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q4 2018 was Renaissance Technologies, an estimated $69.5K added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q4 2018 was Vanguard Group, an estimated $34.7K sold.

Based on aggregated 13F filings for Q4 2018.